Voluntary announcement - collaboration development agreement with ailsynbio
Filed with HKEX · Stock code 3692 · · 2 pages · English
Summary by 6ix AI
Hansoh Pharmaceutical Group Company Limited has announced a collaboration development agreement with AilsynBio Limited, focusing on the discovery of novel oral cyclic peptide drug candidates using AilsynBio's AI platform. Under the agreement, Hansoh will have the rights to select targets and acquire intellectual property rights for the corresponding programs, while AilsynBio will receive payments and royalties based on future sales. The company states that the payments related to this agreement will be recognized as research and development expenditure and do not constitute notifiable transactions under the Listing Rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Inside information - strategic collaboration and license agreement with roche
- Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
Later from Hansoh Pharmaceutical
- Voluntary announcement - progress on the inclusion of innovative medicines in the 2026 national reimbursement drug list
- Voluntary announcement - marketing authorization of Aumolertinib receives positive opinion from the chmp of the ema
- Voluntary announcement - new drug application of socrodeucitinib tablets (HS-10374) accepted by the national medical products administration
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical